Medicinal Cannabis (MedCan 3) - randomised, multicentre, double blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer

This Earmarked Scholarship project is aligned with a recently awarded Category 1 research grant. It offers you the opportunity to work with leading researchers and contribute to large projects of national significance.

Supervisor – Professor Phillip Good,

This project will be a randomised, multicentre, double blind, placebo controlled 2 arm trial to examine an escalating dose of two components found in MC (THC:CBD oil in a 1:20 ratio). Our primary outcome is the improvement in total symptom burden at day 14. Secondary outcomes include the assessment of tolerability and adverse effect profile of this MC combination, the effect on sleep, quality of life and an investigation into how genetic profiles influence clinical outcomes. An important consumer aspect of this study will investigate carers’ individual and social perceptions of MC use and patient perceptions of overall benefit of MC on their quality of life. Our studies will define the role of MC in symptom relief and critically inform clinician prescribing and national policy decisions regarding funding and regulation of MCs.

Preferred educational background

Applications will be judged on a competitive basis taking into account the applicant's previous academic record, publication record, honours and awards, and employment history.Preferred educational background

A working knowledge of research methodology, clinical medicine and training in palliative medicine would be of benefit to someone working on this project.

The applicant will demonstrate academic achievement in the field(s) of medicine and the potential for scholastic success.

A background or knowledge of clinical medicine in palliative care is highly desirable.

*The successful candidate must commence by Research Quarter 2, 2023. You should apply at least 3 months prior to the research quarter commencement date. International applicants may need to apply much earlier for visa reasons.

Apply now